Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency - guidance (TA709)

NICE recommends use of pembrolizumab in these conditions providing criteria outlined in the guidance is met. Clinical trial evidence that shows pembrolizumab increases time until the condition worsens compared to current treatments if such criteria is met.

Source:

National Institute for Health and Care Excellence